TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04149301

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D gait analysis
Description: Children will have their walking measured in the gait laboratory to record their kinematics and kinetics along with electromyography (EMG) from key muscle groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D gait analysis
Description: Children will have their walking measured in the gait laboratory to record their kinematics and kinetics along with electromyography (EMG) from key muscle groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D gait analysis
Description: Children will have their walking measured in the gait laboratory to record their kinematics and kinetics along with electromyography (EMG) from key muscle groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D gait analysis
Description: Children will have their walking measured in the gait laboratory to record their kinematics and kinetics along with electromyography (EMG) from key muscle groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: The children will have two MRI scans taken - one with the foot loaded and one with no load applied.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: The children will have two MRI scans taken - one with the foot loaded and one with no load applied.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: The children will have two MRI scans taken - one with the foot loaded and one with no load applied.
Study: NCT04554498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1) high flux hemodiafiltration thrice -weekly during a 24 month follow-up
Description: 1. the comparison of the effects of the two membranes on the serum levels of albumin, B2M, CRP, myoglobin, light chains, retinol binding protein, homocysteine, p-cresol, indoxyl sulfate, BPA, alpha-1-microglobulin (A1M), FGF23 (fibroblast growth factor 23), and inflammatory cytokines;~2. the evaluation of the changes induced by the two filters on lymphocyte subsets, monocyte activation and senescence, and apoptosis rate;~3. the definition of the impact of the two membranes on the accumulation of AGEs as an index of metabolic and oxidative stress, determined by a non-invasive method based on the measurement of skin autofluorescence through a dedicated device (AGE Reader, DiagnOptics Technologies BV, Groningen, Netherlands).
Study: NCT04149301

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: The children will have two MRI scans taken - one with the foot loaded and one with no load applied.
Study: NCT04554498

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1) high flux hemodiafiltration thrice -weekly during a 24 month follow-up
Description: 1. the comparison of the effects of the two membranes on the serum levels of albumin, B2M, CRP, myoglobin, light chains, retinol binding protein, homocysteine, p-cresol, indoxyl sulfate, BPA, alpha-1-microglobulin (A1M), FGF23 (fibroblast growth factor 23), and inflammatory cytokines;~2. the evaluation of the changes induced by the two filters on lymphocyte subsets, monocyte activation and senescence, and apoptosis rate;~3. the definition of the impact of the two membranes on the accumulation of AGEs as an index of metabolic and oxidative stress, determined by a non-invasive method based on the measurement of skin autofluorescence through a dedicated device (AGE Reader, DiagnOptics Technologies BV, Groningen, Netherlands).
Study: NCT06227754

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI group
Description: The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography-guided PCI group
Description: \[Stent Optimization\]~1. Stent Expansion:~   Visually assess residual angiographic diameter stenosis \<10% AND~   ① In non-LM lesions: In-stent minimal lumen area (MSA) \>80% of the average reference lumen area OR \>4.5 mm2~   ② In LM lesion: MSA\>7 mm2 for distal LM and \>8 mm2 for proximal LM~2. Stent Apposition:~   No major malapposition (defined as a distance from stent strut to adjacent intima ≥400 um and \< 1mm length) of the stent over its entire length against the vessel wall~3. Edge Dissection:~No major edge dissection in the proximal or distal reference segments, defined as 5 mm from the edge of the stent, extended to media layer with potential to provoke flow disturbances (defined as \>60° of the circumference of the vessel at site of dissection and/or \>2 mm in length of dissection flap)
Study: NCT05745636

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli, mustard, vitamin C
Description: 2 capsules per day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules per day for 4 weeks.
Study: NCT05385900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab combination with anlotinib and chemotherapy
Description: Penpulimab: fixed dose of 200 mg, administered on day 1 of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14 of each cycle, orally once a day, about half an hour before breakfast (the time of daily administration should be the same as possible), with warm water, every 3 weeks Repeat 1 time
Study: NCT05430464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1726nm Laser System
Description: Subjects will receive 1726nm laser treatments on one side of the face

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser System
Description: Subjects will receive sham laser treatments on the other side of the face.
Study: NCT05632484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord blood sampling
Description: Collection of 2 milliliters (mL) of cord blood on an Ethylenediaminetetraacetic acid (EDTA) tube, on the day of delivery and after cutting the umbilical cord, for genetic testing

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord blood sampling
Description: Collection of 50 to 100 mL of cord blood from the cord blood collection bag

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord sampling
Description: Collection of 20 centimeters (cm) of umbilical cord
Study: NCT04875260

Intervention type: OTHER
Intervention: Critical Care
Description: Critical care in the intensive care units
Study: NCT05943587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: culture-sensitive PNE4kids
Description: Culturally adapted PNE4kids used by physiotherapists worldwide in chronic pain rehabilitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard education
Description: Standard education used by physiotherapists worldwide in chronic pain rehabilitation.
Study: NCT06366893

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA/AA emulsion supplement for preterm infant
Description: Enteral supplementation of DHA/AA emulsion
Study: NCT05080660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT05752981

Intervention type: DEVICE
Intervention: multichannel time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS)
Description: Participants will be monitored during surgery using the multichannel time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS). This study is observational in nature and no intervention will be applied based on the results of the tr-fNIRS device.
Study: NCT05683223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT for Social Anxiety Disorder
Description: Initial CBT will consist of 12 weekly, 2.5-hour group sessions. Later sessions (after session 7) become more individualized as the exposure practices are tailored to the individual participant's concerns. Most often, the exposures are completed outside the group environment. Session content includes various cognitive behavioral strategies tailored to SAD, such as psychoeducation, examining and challenging cognitive distortions, and exposure exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT for Social Anxiety Disorder
Description: Initial CBT will consist of 12 weekly, 2.5-hour group sessions. Later sessions (after session 7) become more individualized as the exposure practices are tailored to the individual participant's concerns. Most often, the exposures are completed outside the group environment. Session content includes various cognitive behavioral strategies tailored to SAD, such as psychoeducation, examining and challenging cognitive distortions, and exposure exercises.
Study: NCT04970238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Test drug: drug preparation method: 5ml (12.5mg) levosimendan injection was mixed with 500ml 5% glucose injection, the initial loading dose was 6 µg / kg for 10 minutes, followed by continuous infusion of 0.1 µg/ kg / min for 24 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Control drug: 5% glucose injection, intravenous injection method is the same as the experimental group pump dose, the initial load dose of treatment is 6 µg / kg for 10 minutes, followed by continuous infusion of 0.1 µg / kg / min for 24 hours.
Study: NCT05683223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Non-responders will initiate sertraline at baseline (week 0) with 25 mg/day followed by a dose increase to 50 mg/day at week 1, 100 mg at week 4, 150 mg at week 6, and 200 mg at week 8. Upward dose titration may be slowed and the dose decreased if necessary due to side effects, but the clinician will attempt to titrate all symptomatic participants up to 200 mg/day if tolerated by week 8, with the last dose increase allowed at week 10. Participants will be assessed at each visit by the study psychiatrist for purposes of dose titration and monitoring. Symptomatic participants unable to reach 200 mg/day of sertraline due to side effects will be maintained in the trial if they are on at least 50 mg/day by week 8; all symptomatic participants will be titrated to their maximally tolerated dose (\< 200 mg/day sertraline). Any participant unable to tolerate sertraline will be discontinued and referred for clinical treatment.
Study: NCT06138795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2389
Description: Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.
Study: NCT05683223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual CBT for Social Anxiety Disorder
Description: Participants who show no or only partial response to the initial group CBT will continue with an individual, tailored form of CBT plus adjunctive SSRI. The format of CBT will include
Study: NCT06138795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.
Study: NCT05292131

Intervention type: DRUG
Group type: OTHER
Intervention: bimekizumab
Description: Study participants will receive a single dose of bimekizumab (BKZ) administered subcutaneously in the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimekizumab
Description: Study participants will receive a single dose of bimekizumab (BKZ) administered subcutaneously in the Treatment Period.
Study: NCT05254730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: macro-micro tetrodes for intracranial recording
Description: novel design of tetrode micro electrodes within the standard macro intracranial electrodes used clinically for identification of the epileptogenic zone
Study: NCT04872712

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Press needles
Description: Manual acupuncture using press needles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Filiform Needles
Description: Manual acupuncture using filiform needles
Study: NCT00013026

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CHF Self-management Education (Web-based Education)
Study: NCT06466668

Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep study
Description: All subjects will undergo a polysomnography at home

Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep study
Description: All subjects will undergo a polysomnography at home

Intervention type: DIAGNOSTIC_TEST
Intervention: stress-related biomarkers and microbiome composition will be assessed using saliva samples
Description: stress and stress-related inflammatory biomarkers will be tested using saliva sample

Intervention type: DIAGNOSTIC_TEST
Intervention: stress-related biomarkers and microbiome composition will be assessed using saliva samples
Description: stress and stress-related inflammatory biomarkers will be tested using saliva sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Audiological tests
Description: Pure tone audiometry, Uncomfortable Loudness Levels, Distortion-Product Otoacoustic Emissions, tablet test for hyperacusis, tablet test for hearing screening

Intervention type: DIAGNOSTIC_TEST
Intervention: Audiological tests
Description: Pure tone audiometry, Uncomfortable Loudness Levels, Distortion-Product Otoacoustic Emissions, tablet test for hyperacusis, tablet test for hearing screening
Study: NCT05073081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehab for LSS
Description: The 8-week prehabilitation program will be delivered online by physiotherapists, chiropractors, and kinesiologists through synchronous and asynchronous exercise sessions, along with online educational sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in the control group will receive usual care as per surgeons' current practice.
Study: NCT06138795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.
Study: NCT06003569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BACK-S
Description: BACK = Better Asthma Control for Kids:~The BACK -Standard package includes a tailor-and-adapt to context strategy of approaches necessary to implement BACK in schools based on our past work, operationalized as an implementation blueprint to coordinate with partner roles of child/family, schools, healthcare teams and community resource agencies. This includes a facilitation strategy to support problem-solving through regular learning collaborative meetings for asthma navigators (bi-weekly), school nurses (monthly to bi-monthly) and health care champions (quarterly).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BACK-E
Description: The BACK-Enhanced package includes the BACK-Standard package plus an Enhanced strategy to develop interrelationships with students/family, schools, and community agencies providing resources to address social determinants of health.
Study: NCT05235139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental (ISOPURE 1.2.3.)
Description: Implantation of premium monofocal IOL ISOPURE 1.2.3.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation active comparator (Acrysof Vivity)
Description: Implantation of EDOF IOL Acrysof Vivity
Study: NCT06087692

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: -based game therapy applied in addition to aerobic exercise

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: -based game therapy applied in addition to aerobic exercise

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: -based game therapy applied in addition to aerobic exercise
Study: NCT06640751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health behavior intervention
Description: The program is a group-based intervention provided by a healthcare team consisting of researchers, cardiologists, family doctors, community healthcare workers, psychologists, and health education specialists. The intervention is structured around three modules-predisposing, enabling, and reinforcing factors-that provide a framework for educational interventions aimed at promoting healthy behaviors in hypertensive patients.
Study: NCT06323668

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac implantable electronic device extraction
Description: The CIED removal will be done as soon as possible within 7 days.
Study: NCT04559360

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRESTOapp
Description: The intervention group will be asked to use the app for a period of 2 months.
Study: NCT05300633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-Based Community Reinforcement Approach and Family Training-Early Psychosis Intervention (CRAFT-EPI)
Description: Behavioral therapy adapted for families of young people experiencing early psychosis delivered via telemedicine to groups following an individual orientation. Group session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, and problem solving. A happiness scale will be completed at each session. Will be provided in the context of an early psychosis intervention program that provides coordinated specialty care to 16- to 29-year-olds experiencing any diagnosis that can manifest as early psychosis.
Study: NCT06339918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KegelExercise
Description: Kegel exercises (also called pelvic floor exercises)will be used to strengthen the pelvic floor muscles it will involve repeatedly contracting and relaxing the muscles that form part of the pelvic floor.
Study: NCT06087146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sauerkraut (Brassica oleracea v. capitata)
Description: The research material is a donation from the company Eko Bio Zrnje, Vrbovec, Croatia. It's grated pickle cabbage produced by fermentation in a saline solution (NaCl) in which the fermentation was stopped by pasteurization and was packed in glass 500g jars. The nutritional and microbiological composition was tested by the laboratories of the Faculty of Food and Biotechnology, as well as by the cultural laboratory approach confirmed the presence of bacteria that produce lactic acid (4.82·103 (±2.31) CFU/mL)
Study: NCT06339918

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4-7-8 breathing technique
Description: This can be performed in the following way: Participants taking part should locate a comfy spot to sit. Inhale to the count of 4. Hold their breath for 7 counts. To the count of 8, release air via their mouth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-7-8 breathing technique
Description: This can be performed in the following way: Participants taking part should locate a comfy spot to sit. Inhale to the count of 4. Hold their breath for 7 counts. To the count of 8, release air via their mouth.
Study: NCT06283238

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor (ICI) or chemotherapy alone
Description: Immune checkpoint inhibitor (i.e. pembrolizumab, nivolumab, or another checkpoint inhibitor) or chemotherapy alone

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor (ICI) or chemotherapy alone
Description: Immune checkpoint inhibitor (i.e. pembrolizumab, nivolumab, or another checkpoint inhibitor) or chemotherapy alone

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor (ICI) or chemotherapy alone
Description: Immune checkpoint inhibitor (i.e. pembrolizumab, nivolumab, or another checkpoint inhibitor) or chemotherapy alone
Study: NCT06522737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: oral capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: solution for intravenous infusion
Study: NCT05075382

Intervention type: PROCEDURE
Intervention: Elbow surgery for fracture
Description: This group will undergo a surgery in order to fix a broken elbow.
Study: NCT06522737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: solution for intravenous infusion
Study: NCT04607252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin plus Megestrol acetate
Description: metformin 1500mg, per day, oral; megestrol acetate 160mg per day, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate
Description: megestrol acetate 160mg per day, oral